Aytu Bioscience Inc Stock OTC Bulletin Board
Equities
AYTU
US0547542052
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
|
05-15 | Transcript : Aytu BioPharma, Inc., Q3 2024 Earnings Call, May 15, 2024 | |
05-15 | Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Sales 2024 * | 81.33M 111M | Sales 2025 * | 78.22M 107M | Capitalization | 16.72M 22.87M |
---|---|---|---|---|---|
Net income 2024 * | -13M -17.78M | Net income 2025 * | 3M 4.1M | EV / Sales 2024 * | 0.21 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.21 x |
P/E ratio 2024 * |
-1.12
x | P/E ratio 2025 * |
4.31
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.67% |
Latest transcript on Aytu Bioscience Inc
Managers | Title | Age | Since |
---|---|---|---|
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 15-04-15 |
Jarrett Disbrow
FOU | Founder | 49 | 15-04-15 |
Mark Oki
DFI | Director of Finance/CFO | 55 | 22-01-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vivian Liu
BRD | Director/Board Member | 62 | 22-06-30 |
Jarrett Disbrow
FOU | Founder | 49 | 15-04-15 |
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 15-04-15 |
1st Jan change | Capi. | |
---|---|---|
+61.53% | 848B | |
+34.02% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+11.21% | 234B | |
+15.40% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |
- Stock Market
- Equities
- AYTU Stock
- AYTU Stock